Daiichi Sankyo’s DXd ADC Pipeline Advances: ENHERTU Files for HER2-Low/Ultra-Low Breast Cancer, Dato-DXd Gains FDA Breakthrough Therapy for EGFRm NSCLC

August 9, 2026

Quartr Japan

Overview

Daiichi Sankyo reported significant progress in its DXd antibody-drug conjugate (ADC) pipeline, with ENHERTU showing efficacy in HER2-low and ultra-low breast cancer, leading to global regulatory submissions. Datopotamab deruxtecan (Dato-DXd) received FDA Breakthrough Therapy designation for EGFR-mutated non-small cell lung cancer, with an accelerated approval submission based on TROPION-Lung05 data. The company is also integrating precision medicine strategies, leveraging large datasets and AI-driven multiplex IHC for translational research, solidifying its leadership in next-generation cancer therapies.

In Depth

Key Findings

Daiichi Sankyo has reported substantial advancements in its innovative DXd antibody-drug conjugate (ADC) pipeline. Notably, ENHERTU (trastuzumab deruxtecan) has demonstrated significant efficacy in HER2-low and ultra-low expressing breast cancer, a patient population previously underserved by HER2-targeted therapies, leading to active global regulatory submissions. Furthermore, Datopotamab deruxtecan (Dato-DXd), another leading DXd ADC, has been granted Breakthrough Therapy designation by the U.S. FDA for EGFR-mutated non-small cell lung cancer (NSCLC), with an accelerated approval submission underway based on data from the TROPION-Lung05 study.

Technical / Clinical Details

ENHERTU is an ADC comprising an anti-HER2 antibody linked to a potent topoisomerase I inhibitor. Beyond its established efficacy in HER2-positive breast cancer, clinical data have now confirmed its activity in HER2-low (IHC 1+/FISH- or IHC 2+/FISH-) and even HER2-ultra-low (IHC 0) breast cancers. This expansion targets a large patient population with significant unmet needs. Dato-DXd, a TROP2-directed ADC, received the Breakthrough Therapy designation for EGFR-mutated NSCLC, recognizing its potential to offer substantial improvement over existing therapies for a serious condition. This designation expedites the development and review process for drugs that treat serious conditions and demonstrate preliminary clinical evidence of substantial improvement. Daiichi Sankyo is also deeply integrating precision medicine strategies across its pipeline, utilizing large datasets and AI-driven multiplex immunohistochemistry (IHC) to enhance translational research. This approach aims to identify predictive biomarkers and better understand drug mechanisms, thereby optimizing patient selection and therapeutic outcomes for their ADC candidates.

Background & Context

ADCs have become a cornerstone of modern oncology, selectively delivering highly potent cytotoxic agents to cancer cells via an antibody targeting a specific tumor antigen. Daiichi Sankyo’s proprietary DXd ADC platform has established itself as a leader in this class due to its high potency and favorable therapeutic index. The expansion of ENHERTU’s utility to HER2-low and ultra-low breast cancer is particularly impactful, as these patients previously had limited HER2-targeted treatment options. Similarly, EGFR-mutated NSCLC is a challenging area, especially for patients who develop resistance to initial EGFR tyrosine kinase inhibitor (TKI) therapies. Dato-DXd’s Breakthrough Therapy designation reflects the high unmet need in this population and the drug’s potential to provide a novel therapeutic alternative.

Strategic Significance & Outlook

The continued progress of Daiichi Sankyo’s DXd ADC pipeline is set to significantly impact cancer treatment in the coming years. ENHERTU’s potential approval for HER2-low and ultra-low breast cancer will benefit a broader population of breast cancer patients, while the accelerated approval pathway for Dato-DXd offers new hope for those with EGFR-mutated NSCLC. The company’s commitment to precision medicine and AI-driven research provides a robust foundation for developing personalized and highly effective therapies. This strategy is expected to further solidify Daiichi Sankyo’s leadership in the global oncology market, ensuring it continues to deliver groundbreaking solutions for challenging cancers.

Source: https://quartr.com/events/daiichi-sankyo-company-4568-status-update_F9EXqjpy

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.